Viking Therapeutics reported interim Phase 2 data showing participants maintained prior weight loss on less-frequent VK2735 dosing over a 12-week period.
On September 22, 2026, Viking Therapeutics reported interim topline results from a randomized clinical trial of VK2735. This investigational medication is a dual GLP-1 and GIP receptor agonist being developed for obesity and metabolic disorders. The company shared that participants who switched to every-other-week or monthly dosing maintained a substantial portion of their prior weight loss. These early findings address a major practical challenge in modern obesity treatment.
Medical professionals are increasingly focused on how to preserve weight loss while reducing the treatment burden for patients. The broader implication is that obesity-drug development is entering a new phase. Researchers are increasingly examining not only maximum weight loss but also long-term maintenance strategies. Evaluating dosing flexibility, tolerability and treatment persistence is becoming just as important as the initial clinical results.
Understanding this study requires a closer look at how these metabolic medications function. VK2735 targets the GLP-1 and GIP pathways, which makes it mechanistically related to other emerging treatments. These biological pathways regulate appetite and influence how the body processes energy. During the initial phase of treatment, patients often experience significant changes in hunger signals. This biological shift typically leads to a notable reduction in body weight without relying entirely on intense restriction.
Maintaining that progress long-term presents a different set of challenges. Weight management relies heavily on consistent metabolic signals, and removing treatment abruptly can cause appetite hormones to rebound. Viking Therapeutics chief executive Brian Lian noted that VK2735 has a specific pharmacokinetic profile. The company believes the drug's half-life might allow it to remain active in the body for longer periods. This extended activity could theoretically support metabolic stability even when doses are spaced further apart.
When the new class of weight-loss medications started dominating the news, the media reaction was entirely polarized. It was presented as either a complete solution or a moral failing. I saw a huge need for calm and objective reporting. We decided to cover these medications exactly like any other tool by evaluating the clinical data without any judgment.
The response from our readers showed just how starved people were for facts over feelings. The reality of the VK2735 data requires exactly this kind of careful and objective reading. First, VK2735 is still an investigational clinical-stage candidate and is not currently approved for use. Second, the maintenance phase of this study lasted only 12 weeks after the induction period.
Maintaining weight loss over three months does not prove that monthly dosing will preserve those results indefinitely. Additionally, the participants were otherwise healthy adults with obesity. These early findings may not generalize to people with type 2 diabetes, cardiovascular disease or older age. Third, the highest reported retention percentages came from relatively small dosing cohorts.
For example, there were only 12 participants in the highest-retaining every-other-week arm. There were just 11 participants in one monthly arm that transitioned from 17.5 milligrams weekly. Relying on such small groups means we cannot present these results as a guaranteed outcome for all patients. Finally, readers must distinguish between weight loss maintained and additional weight loss.
Keeping 90 percent of prior weight loss does not mean patients lost an additional 90 percent of their body weight. It simply means they retained most of the weight they had already lost during the initial treatment phase. Louis Aronne, a metabolic-research professor and paid consultant to Viking, noted that maintaining 75 percent of prior weight loss could be clinically meaningful.
The VK2735 trial enrolled approximately 180 otherwise healthy adults with obesity. The company defined obesity for this study as a baseline body mass index of at least 30. Everyone began with a 21-week induction phase where they received once-weekly injections or a placebo. During this weekly-treatment phase, the medication groups recorded approximately 16 to 19 percent weight loss.
By week 21, the company reported significant milestones across the combined medication groups. The active treatment cohorts achieved the following weight-loss thresholds:
The placebo group saw far less change, with zero percent reaching the higher weight-loss thresholds. Following this induction, some participants entered the 12-week maintenance phase to test altered schedules. The combined group that switched to every-other-week dosing maintained 90 percent of their prior weight loss by week 33. Individual arms in this category maintained 83 percent, 90 percent and 97 percent of prior mean weight loss.
The highest result came from a cohort moving from 17.5 milligrams weekly to 10 milligrams every other week. Participants transitioned to monthly dosing maintained an average of 85 percent of their prior weight loss. Individual monthly arms reported maintenance rates between 82 percent and 90 percent. Interestingly, the company noted that including one excluded outlier would have produced a 99 percent maintenance result for one monthly cohort.
Participants transitioned to a placebo maintained 61 percent of their previous weight loss over the same 12-week window. The company reported a statistically significant separation from the placebo as early as four weeks after the transition. An exploratory cohort that continued receiving 17.5 milligrams weekly recorded approximately 21.7 percent mean weight loss from baseline at week 33. The placebo group recorded a 0.3 percent weight gain in that same period.
Viking reported one treatment discontinuation in the combined every-other-week group and three in the combined monthly group. The company also stated that gastrointestinal adverse-event rates were not meaningfully different from the placebo during maintenance.
The findings point to an important shift in how the medical community approaches lasting metabolic health. A successful obesity treatment plan must consider how to navigate long-term maintenance rather than just the initial drop on the scale. Researchers will need to track participants for much longer than 12 weeks to see if less-frequent dosing is truly viable over years. Larger and longer trials are necessary to rule out uncommon or delayed side effects completely.
Sustainable weight management should also be evaluated through outcomes far beyond the scale. A holistic approach considers physical function alongside cardiometabolic risk and muscle preservation. Viking’s chief executive specifically cited cardiovascular health and physical function as potential long-term benefits of effective weight control. However, these specific benefits were not directly demonstrated by this short maintenance study.
Future research will also likely expand to include different administration methods. In late 2025, Viking reported that its Phase 3 obesity trials for the medication were fully enrolled. The company also indicated it plans to study oral maintenance regimens in a subsequent part of this trial. Understanding the maintenance challenge for weight-loss medications requires patience and ongoing medical supervision.
Until we have peer-reviewed data and regulatory approval, these interim results remain purely investigational. Patients should always consult their prescribing clinician before adjusting the frequency of any current treatment. Attempting a self-directed transition from weight loss to maintenance by altering medication schedules without medical guidance is never a safe approach.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
